Adjuvant cholylsarcosine during ursodeoxycholic acid treatment of primary biliary cirrhosis

Paola Ricci, Alan F. Hofmann, L. R. Hagey, Roberta A. Jorgensen, E. Rolland Dickson, Keith Lindor

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

We postulated that coadministration of cholylsarcosine with ursodeoxycholic acid might provide additional benefit to primary biliary cirrhosis patients with an incomplete response to ursodeoxycholic acid. Our aim was to test the tolerability and the effect of adjuvant cholylsarcosine on liver tests and plasma cholesterol in primary biliary cirrhosis patients receiving ursodeoxycholic acid. Four primary biliary cirrhosis patients, who, despite more than a year of ursodeoxycholic acid therapy, had one or more liver tests persistently equal to or greater than twice the upper limit of normal, received cholylsarcosine (12-15 mg/kg/day) in addition to ursodeoxycholic acid (13-15 mg/kg/day) for six weeks in an open label study. Values of liver tests and plasma cholesterol, determined every two weeks, remained unchanged. One patient discontinued cholylsarcosine at week 4 because of new-onset pruritus. Analysis of duodenal bile acids in one patient showed 52% enrichment in cholylsarcosine and hydrophilic bile acids constituted 87% of total bile acids. It is concluded that the addition of cholylsarcosine to ursodeoxycholic acid did not influence liver tests in four primary biliary cirrhosis patients who had not responded completely to ursodeoxycholic acid alone. Cholylsarcosine was absorbed and became a dominant biliary bile acid; its administration was associated with increased pruritus.

Original languageEnglish (US)
Pages (from-to)1292-1295
Number of pages4
JournalDigestive Diseases and Sciences
Volume43
Issue number6
DOIs
StatePublished - 1998
Externally publishedYes

Fingerprint

Ursodeoxycholic Acid
Biliary Liver Cirrhosis
Bile Acids and Salts
Liver
Pruritus
Therapeutics
Cholesterol
cholylsarcosine

Keywords

  • Cholylsarcosine
  • Primary biliary cirrhosis
  • Ursodeoxycholic acid

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Adjuvant cholylsarcosine during ursodeoxycholic acid treatment of primary biliary cirrhosis. / Ricci, Paola; Hofmann, Alan F.; Hagey, L. R.; Jorgensen, Roberta A.; Dickson, E. Rolland; Lindor, Keith.

In: Digestive Diseases and Sciences, Vol. 43, No. 6, 1998, p. 1292-1295.

Research output: Contribution to journalArticle

Ricci, Paola ; Hofmann, Alan F. ; Hagey, L. R. ; Jorgensen, Roberta A. ; Dickson, E. Rolland ; Lindor, Keith. / Adjuvant cholylsarcosine during ursodeoxycholic acid treatment of primary biliary cirrhosis. In: Digestive Diseases and Sciences. 1998 ; Vol. 43, No. 6. pp. 1292-1295.
@article{afac3811e0a9454295cefa6a705435c7,
title = "Adjuvant cholylsarcosine during ursodeoxycholic acid treatment of primary biliary cirrhosis",
abstract = "We postulated that coadministration of cholylsarcosine with ursodeoxycholic acid might provide additional benefit to primary biliary cirrhosis patients with an incomplete response to ursodeoxycholic acid. Our aim was to test the tolerability and the effect of adjuvant cholylsarcosine on liver tests and plasma cholesterol in primary biliary cirrhosis patients receiving ursodeoxycholic acid. Four primary biliary cirrhosis patients, who, despite more than a year of ursodeoxycholic acid therapy, had one or more liver tests persistently equal to or greater than twice the upper limit of normal, received cholylsarcosine (12-15 mg/kg/day) in addition to ursodeoxycholic acid (13-15 mg/kg/day) for six weeks in an open label study. Values of liver tests and plasma cholesterol, determined every two weeks, remained unchanged. One patient discontinued cholylsarcosine at week 4 because of new-onset pruritus. Analysis of duodenal bile acids in one patient showed 52{\%} enrichment in cholylsarcosine and hydrophilic bile acids constituted 87{\%} of total bile acids. It is concluded that the addition of cholylsarcosine to ursodeoxycholic acid did not influence liver tests in four primary biliary cirrhosis patients who had not responded completely to ursodeoxycholic acid alone. Cholylsarcosine was absorbed and became a dominant biliary bile acid; its administration was associated with increased pruritus.",
keywords = "Cholylsarcosine, Primary biliary cirrhosis, Ursodeoxycholic acid",
author = "Paola Ricci and Hofmann, {Alan F.} and Hagey, {L. R.} and Jorgensen, {Roberta A.} and Dickson, {E. Rolland} and Keith Lindor",
year = "1998",
doi = "10.1023/A:1018868126743",
language = "English (US)",
volume = "43",
pages = "1292--1295",
journal = "American Journal of Digestive Diseases",
issn = "0002-9211",
publisher = "Springer New York",
number = "6",

}

TY - JOUR

T1 - Adjuvant cholylsarcosine during ursodeoxycholic acid treatment of primary biliary cirrhosis

AU - Ricci, Paola

AU - Hofmann, Alan F.

AU - Hagey, L. R.

AU - Jorgensen, Roberta A.

AU - Dickson, E. Rolland

AU - Lindor, Keith

PY - 1998

Y1 - 1998

N2 - We postulated that coadministration of cholylsarcosine with ursodeoxycholic acid might provide additional benefit to primary biliary cirrhosis patients with an incomplete response to ursodeoxycholic acid. Our aim was to test the tolerability and the effect of adjuvant cholylsarcosine on liver tests and plasma cholesterol in primary biliary cirrhosis patients receiving ursodeoxycholic acid. Four primary biliary cirrhosis patients, who, despite more than a year of ursodeoxycholic acid therapy, had one or more liver tests persistently equal to or greater than twice the upper limit of normal, received cholylsarcosine (12-15 mg/kg/day) in addition to ursodeoxycholic acid (13-15 mg/kg/day) for six weeks in an open label study. Values of liver tests and plasma cholesterol, determined every two weeks, remained unchanged. One patient discontinued cholylsarcosine at week 4 because of new-onset pruritus. Analysis of duodenal bile acids in one patient showed 52% enrichment in cholylsarcosine and hydrophilic bile acids constituted 87% of total bile acids. It is concluded that the addition of cholylsarcosine to ursodeoxycholic acid did not influence liver tests in four primary biliary cirrhosis patients who had not responded completely to ursodeoxycholic acid alone. Cholylsarcosine was absorbed and became a dominant biliary bile acid; its administration was associated with increased pruritus.

AB - We postulated that coadministration of cholylsarcosine with ursodeoxycholic acid might provide additional benefit to primary biliary cirrhosis patients with an incomplete response to ursodeoxycholic acid. Our aim was to test the tolerability and the effect of adjuvant cholylsarcosine on liver tests and plasma cholesterol in primary biliary cirrhosis patients receiving ursodeoxycholic acid. Four primary biliary cirrhosis patients, who, despite more than a year of ursodeoxycholic acid therapy, had one or more liver tests persistently equal to or greater than twice the upper limit of normal, received cholylsarcosine (12-15 mg/kg/day) in addition to ursodeoxycholic acid (13-15 mg/kg/day) for six weeks in an open label study. Values of liver tests and plasma cholesterol, determined every two weeks, remained unchanged. One patient discontinued cholylsarcosine at week 4 because of new-onset pruritus. Analysis of duodenal bile acids in one patient showed 52% enrichment in cholylsarcosine and hydrophilic bile acids constituted 87% of total bile acids. It is concluded that the addition of cholylsarcosine to ursodeoxycholic acid did not influence liver tests in four primary biliary cirrhosis patients who had not responded completely to ursodeoxycholic acid alone. Cholylsarcosine was absorbed and became a dominant biliary bile acid; its administration was associated with increased pruritus.

KW - Cholylsarcosine

KW - Primary biliary cirrhosis

KW - Ursodeoxycholic acid

UR - http://www.scopus.com/inward/record.url?scp=0031744558&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031744558&partnerID=8YFLogxK

U2 - 10.1023/A:1018868126743

DO - 10.1023/A:1018868126743

M3 - Article

VL - 43

SP - 1292

EP - 1295

JO - American Journal of Digestive Diseases

JF - American Journal of Digestive Diseases

SN - 0002-9211

IS - 6

ER -